Latest News and Press Releases

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease ...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022, at 5:00 p.m. ET Filed Investigational New Drug (IND) application with U.S. Food and Drug...

CELEBRATION, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel...

Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022 CELEBRATION, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH)...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET CELEBRATION, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS:...

Cardiovascular safety is a key component of the KP1077 product profile; Topline data comparing SDX to other stimulant treatments expected in Q3 2022 CELEBRATION, Fla., April 19, 2022 (GLOBE...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...

CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...

Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep...

KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm,...